Evofem Biosciences (EVFM) Investor presentation summary

Strategic focus and product portfolio

• Commercializing two FDA-approved products: a hormone-free, on-demand contraceptive vaginal gel and a single-dose oral treatment for bacterial vaginosis and trichomoniasis.

• Both products are expanding into international markets, with initial launches planned in the UAE and broader MENA region.

• The contraceptive gel targets a U.S. addressable market of 26.2 million women, with significant sales potential per 1% market share.

• The oral treatment addresses prevalent sexual health conditions, with a synergistic fit to the existing sales force.

• Both products are protected by multiple Orange Book-listed patents, providing exclusivity into the 2030s.

Market opportunity and growth drivers

• U.S. contraceptive market valued at $8.8 billion in 2024, with 9.8 million women using non-hormonal methods.

• Social media and targeted campaigns have increased brand awareness, especially among women ages 18–25.

• The "Say Vagina" campaign generated over 2.5 million views and tripled website traffic.

• GLP-1 users represent a new $877 million net sales opportunity for the contraceptive gel.

• Five consecutive years of net sales growth, despite no marketing spend since Q4 2022.

Operational and financial initiatives

• Initiatives underway to reduce cost of goods sold (COGS) for both products by 55–60% through new manufacturing partners.

• Ex-U.S. expansion is expected to diversify and grow revenue streams, starting with the UAE.

• License and supply agreements in MENA provide upfront payments, regulatory milestones, and sales-based milestones.

• New manufacturing processes for both products are expected to be operational by 2027.

• Ongoing efforts to maintain strong intellectual property protection and defend against generic competition.